These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16678459)

  • 1. Molecular targets and the treatment of myeloid leukemia.
    Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
    Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends].
    Ishizawa J; Saya H
    Nihon Rinsho; 2009 Oct; 67(10):1932-7. PubMed ID: 19860193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based therapy for leukemia: a lesson from ATRA therapy.
    Naoe T
    Nagoya J Med Sci; 2001 Nov; 64(3-4):103-8. PubMed ID: 11820331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.
    Hu J; Zhou GB; Wang ZY; Chen SJ; Chen Z
    Adv Cancer Res; 2007; 98():191-220. PubMed ID: 17433911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathophysiology and treatment of acute myeloid leukemia].
    Naoe J
    Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Michor F
    Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia, an effective model for chemical biology and target therapy.
    Chen GQ; Wang LS; Wu YL; Yu Y
    Acta Pharmacol Sin; 2007 Sep; 28(9):1316-24. PubMed ID: 17723165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
    Zhou GB; Li G; Chen SJ; Chen Z
    Acta Pharmacol Sin; 2007 Sep; 28(9):1434-49. PubMed ID: 17723177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ATRA (all-trans retinoic acid) in chronic myeloid leukemia?].
    Rák K
    Orv Hetil; 2002 Jun; 143(23):1449-50; author reply 1450. PubMed ID: 12132331
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
    Jabbour E; Cortes J; Giles F; Kantarjian H
    Cancer J; 2007; 13(6):357-65. PubMed ID: 18032972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.